// App-Quantinova.ai

: Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Researchers

Presenter

  • Joseph Maakaron

Principal Investigators

  • Adam S. Asch

  • Leslie L. Popplewell

  • Graham P. Collins

  • Ian W. Flinn

  • Nilanjan Ghosh

  • Colin Keane

  • Matthew Ku

  • Amitkumar Mehta

  • Mark Roschewski

  • Carol O'Hear

  • Xuehan Ren

  • Bertha Villa

  • Indu Lal

  • Sonali M. Smith

  • Ranjana H. Advani

Medical Centers

  • Department of Hematology and HCT, City of Hope National Medical Center, Duarte, CA

  • Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

  • Stephenson Cancer Center Hematology/Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK

  • Stanford Cancer Institute, Stanford University, Stanford, CA

  • Princess Alexandra Hospital, Brisbane, Australia

  • Levine Cancer Institute, Atrium Health, Charlotte

  • Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom

  • St Vincent's Hospital, University of Melbourne, Melbourne, Australia

  • Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL

  • Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN

  • University of Minnesota, Minneapolis, MN

  • Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL

Locations

  • United States

  • United Kingdom

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Rituximab

Outcome

  • N/A

Study Design

  • Safety

  • Tolerability

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved